NCT05950750 is a clinical trial in TTP - Thrombotic Thrombocytopenic Purpura, sponsored by Turkish Hematology Association.

Who is sponsoring NCT05950750?

NCT05950750 is sponsored by Turkish Hematology Association.

What condition does NCT05950750 study?

NCT05950750 studies TTP - Thrombotic Thrombocytopenic Purpura.

Is NCT05950750 still recruiting?

NCT05950750 is currently recruiting now. Last updated 18 July 2023.

Last reviewed 2023-07-18 · How we verify

NCT05950750

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter Study

Recruiting now Last updated 18 July 2023

What this trial tests

trial in TTP - Thrombotic Thrombocytopenic Purpura in 960 participants. Currently enrolling.

Timeline

21 December 2022

Primary endpoint
21 December 2023

21 December 2026

Quick facts

Lead sponsor	Turkish Hematology Association
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	960
Start date	21 December 2022
Primary completion	21 December 2023
Estimated completion	21 December 2026
Sites	1 location across Turkey (Türkiye)

Conditions studied

TTP - Thrombotic Thrombocytopenic Purpura — all drugs for TTP - Thrombotic Thrombocytopenic Purpura →

Sponsor

Turkish Hematology Association

Who can join

18 and older, any sex, with TTP - Thrombotic Thrombocytopenic Purpura. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

21 hematology centers in Turkey will participate in this noninterventional observational study. The recruitment target is 960 cases. Patients will be followed-up at least 1 year or to the end of the study according to the physicians' discretion, or withdrawal of consent. Recruitment period will be 36 months. Data will be collected via electronic case report form. Since the study cohort does not include only newly diagnosed patients, all aTTP patients will be included to the study, previous treatments and diagnosis information data could also be collected from hospital records. Patients recruitment duration: 3 years (36 months) Patients follow-up duration: 1 year (12 months)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Manifestations, Treatment Characteristics, and Clinical Outcomes in Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP) in a Real-World Setting: An Interim Analysis of the Turkish iTTP Registry
Karakuş S, Bakanay ŞM, Kalayoğlu Beşişik S, Eşkazan AE, et al · · 2025 · PMID 40699136 · DOI 10.4274/tjh.galenos.2025.2025.0134

Verify or expand the search:

Other recruiting trials for TTP - Thrombotic Thrombocytopenic Purpura

Currently open trials in the same condition.

NCT06376786 — Italian iTTP Registry · recruiting
NCT05571774 — Construction of a Database for TTP · recruiting

Other Turkish Hematology Association trials

Trials by the same sponsor.

NCT05979675 — Acute Myeloid Leukemia Registry · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05950750 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Turkish Hematology Association
Last refreshed: 18 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05950750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing